FACTS & FIGURES SERVICE OFFERING DIAVERUM IS ONE OF THE WORLD’S LEADING RENAL CARE SERVICE PROVIDERS, DELIVERING LIFE ENHANCING RENAL CARE WHICH ENABLES PATIENTS TO LIVE A NORMAL, FULFILLING LIFE. THE SERVICE PORTFOLIO INCLUDES PREVENTIVE CARE, HAEMODIALYSIS, HOME CARE, TRANSPLANTATIONS AS WELL AS THE COORDINATION OF VARIOUS RENAL AND NON-RENAL SERVICES INTO A PACKAGE BUILT AROUND THE RENAL PATIENT.
GLOBAL PRESENCE
CLINICS
404
ALBANIA, ARGENTINA, BRAZIL, CHILE, CHINA, FRANCE, GERMANY, HUNGARY, ITALY, KAZAKHSTAN, LITHUANIA, MOROCCO, NORTH MACEDONIA, POLAND, PORTUGAL, ROMANIA, RUSSIA, SAUDI ARABIA, SPAIN, SWEDEN, UK & URUGUAY
CLINICS
ACROSS 22 COUNTRIES
GLOBALLY
PATIENTS
39,000 DIALYSIS PATIENTS AND A LARGE POPULATION OF CKD STAGE 3-4 PATIENTS¹
HEALTHCARE PROFESSIONALS
11,000 HEALTHCARE PROFESSIONALS CONDUCTS MORE THAN 6 MILLION DIALYSIS TREATMENTS PER YEAR ¹Chronic kidney disease stage 3 and 4 referring to 40-85 % loss of kidney function in opposite to stage 5, which requires dialysis or kidney, transplant.
CLINICAL PERFORMANCE DIAVERUM’S INDUSTRY-LEADING MEDICAL OUTCOMES IMPROVE QUALITY OF LIFE FOR PATIENTS AND LOWER TOTAL COST OF CARE FOR HEALTHCARE SYSTEMS. DIAVERUM’S CLINICAL STANDARDS FULFIL AND EXCEED MOST NATIONAL HEALTH AUTHORITIES' STANDARDS AND HAVE RESULTED IN CONSISTENT IMPROVEMENT OF CPM SCORES² AND REDUCTION OF CRUDE MORTALITY RATES AND HOSPITALIZATION RATES IN THE MARKETS IT OPERATES. ²Clinical Performance Measurements (CPM) is a proprietary metric established to evaluate clinical performance within Diaverum’s own clinics
CRUDE MORTALITY RATE % 14,9
14,5
2012
2011
14,7
HOSPITALIZATION DAYS PER PATIENT 9,44
14,6 13,8
2013
2014
2015
13,6
2016
13,6
2017
8,96
8,99
8,71
8,45
13,0
2011
2018
2012
2013
2014
CONSISTENT IMPROVEMENT IN CLINICAL PERFORMANCE MEASUREMENTS (CPM) AT DIAVERUM WORLDWIDE
2015
8,18
8,16
2016
2017
7,70
2018
SCIENTIFIC RESEARCH DIAVERUM’S SCIENTIFIC RESEARCH FOCUSES ON THE NEEDS AND DEMANDS OF THE PATIENTS:
CPM SCORE
• • •
PREVENTION ENHANCED QUALITY OF LIFE EFFICACY OF THE TREATMENT
PATIENT SATISFACTION 93 % OF OUR PATIENTS WOULD RECOMMEND DIAVERUM TO A FRIEND OR RELATIVE 94 % SAY THAT THEY TRUST THE CLINIC TEAM THAT PROVIDES THEIR CARE 89 % BELIEVE THAT THEY ARE RECEIVING THE BEST AVAILABLE CARE OFFERED (RESULTS FROM OUR ANNUAL GLOBAL PATIENT SURVEY 2018, PROVIDED BY AN EXTERNAL COMPANY)
TRAINING STATE OF THE ART EDUCATION PROGRAMMES FOR PHYSICIANS, NURSES AND PATIENTS • • •
COMPANY-WIDE KNOWLEDGE ENHANCEMENT INTERACTIVE TRAINING CURRICULUM, ACCESSIBLE EVERYWHERE ENABELS PATIENTS TO TAKE AN ACTIVE PART IN THEIR HEALTH
404 CLINICS 39,000 PATIENTS 22 COUNTRIES
DIAVERUM TIMELINE
GAMBRO OPENS ITS FIRST DIALYSIS CLINIC IN LUND, SWEDEN
1991
LAUNCH OF DIAVERUM BRAND
DIAVERUM ENTERS GERMANY
159 CLINICS 12,748 PATIENTS 11 COUNTRIES
2008
2009
DIAVERUM ENTERS CHILE, ROMANIA & SAUDI ARABIA
2011
DIAVERUM ENTERS RUSSIA
2013
DIALYSIS SERVICE CONTRACT SIGNED WTH SAUDI MINISTRY OF HEALTH TO CARE FOR MORE THAN 5,000 PATIENTS
2014
DIAVERUM ENTERS ASIAN MARKET (KAZAKHSTAN)
2015
DIAVERUM ENTERS BRAZIL AND NORTH MACEDONIA. OPEN STATE OF THE ART TRANSPLANT CENTER d.INSTITUTE FOR COMPLEX TRANSPLANTS
2018
DIAVERUM ENTERS ALBANIA, MOROCCO & CHINA
2019
DIAVERUM MANAGEMENT CHIEF EXECUTIVE OFFICER, DIMITRIS MOULAVASILIS. Moulavasilis has 26 years’ experience in the healthcare sector, most recently six years as CEO of an international healthcare service company. CHAIRMAN OF THE BOARD, KENNETH BENGTSSON. KEY SHAREHOLDERS, PRIVATE HEALTHCARE INVESTOR BRIDGEPOINT & DIAVERUM MANAGEMENT.
HEAD OFFICE HYLLIE BOULEVARD 35 – SE 215 37 – MALMÖ SWEDEN info@diaverum.com